Financing ·
RedHill Biopharma increases ATM offering capacity for ADSs under H.C. Wainwright agreement
RDHLRedHill Biopharma Ltd.
The company filed a prospectus supplement to raise the maximum aggregate offering amount of American Depositary Shares issuable under its At The Market Offering Agreement with H.C. Wainwright & Co., LLC, originally entered into on February 3, 2025. This administrative update expands the shelf for future equity sales but does not specify a new dollar cap or immediate issuance in this filing. RedHill Biopharma Ltd. is a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory and infectious diseases.